BI665088, a nano-antibody by AblynxTM in partnership with Boehringer IngelheimTM, inhibited atherosclerosis development in human CX3CR1-expressing mice at 30 mg/kg. This evidence concerns the gene CX3CR1 and atherosclerosis.